Evidence reviewed: 9 November 2026. Type 1 diabetes (T1D) is usually an autoimmune disease in which the immune system destroys pancreatic insulin-producing beta cells, leading to profound insulin deficiency. It can begin in childhood or adulthood and requires ongoing insulin replacement once clinical insulin deficiency develops. Modern care combines safe insulin delivery, glucose monitoring, nutrition education, prevention of severe hypoglycemia and diabetic ketoacidosis (DKA). The American Diabetes Association (ADA) Standards of Care in Diabetes—2026 consider continuous glucose monitoring (CGM) standard care for most people with type 1 diabetes and prefer automated insulin delivery (AID) when the patient or caregiver can use it safely [1–4].
Why insulin is necessary in type 1 diabetes
Insulin enables the body to use and store nutrients and suppresses excess hepatic glucose output, lipolysis and ketone production. In T1D, autoimmune loss of beta cells produces insufficient insulin to regulate glucose and prevent ketogenesis. Without insulin, severe hyperglycemia, dehydration, metabolic acidosis and DKA can develop [1,2].
T1D is not caused simply by eating too much sugar, and exercise or a low-carbohydrate diet cannot replace lifesaving insulin in established insulin-dependent disease. Genetic susceptibility, autoimmunity and environmental factors contribute; there is no reliable proven single cause for every individual.
Type 1 versus type 2 diabetes
| Feature | Type 1 diabetes | Type 2 diabetes |
|---|---|---|
| Usual mechanism | Autoimmune beta-cell destruction with severe insulin deficiency. | Insulin resistance and progressive beta-cell dysfunction. |
| Age at onset | Any age; childhood onset common. | Any age, often adult but increasingly younger. |
| Autoantibodies | Often positive for GAD65, IA-2, ZnT8 or insulin autoantibodies. | Usually negative in conventional T2D. |
| Insulin use | Essential lifelong in established disease. | Needed in selected severe or progressive cases, not universally from diagnosis. |
| DKA risk | Significant with insulin interruption or illness. | Also possible, particularly with marked insulin deficiency or SGLT2 inhibitors. |
| Management emphasis | Insulin delivery, CGM/AID, hypoglycemia and ketone safety. | Risk-based glycemic, weight, cardiovascular and kidney treatment. |
Some adults with autoimmune diabetes are initially misclassified as type 2. Body weight, age or a first presentation with mild symptoms cannot reliably distinguish diabetes types; clinicians consider the full presentation and appropriate laboratory evaluation.
Symptoms of newly diagnosed type 1 diabetes
- Frequent urination (polyuria) and increased thirst (polydipsia).
- Unexplained weight loss despite normal or increased food intake.
- Fatigue, blurry vision or reduced exercise capacity.
- Bedwetting in a previously dry child or new nocturia.
- Abdominal pain, nausea, vomiting, deep breathing or fruity breath if DKA develops.
DKA can be the first presentation, particularly when symptoms are missed. Vomiting, confusion, severe dehydration, rapid deep breathing or pronounced drowsiness requires emergency assessment, not delayed routine testing [2,4].
How is diabetes diagnosed?
Diabetes can be diagnosed through established plasma glucose or A1C criteria when testing conditions are appropriate. Examples include A1C at least 6.5%, fasting plasma glucose at least 126 mg/dL (7.0 mmol/L), or random plasma glucose at least 200 mg/dL (11.1 mmol/L) with classic symptoms. In people without unequivocal hyperglycemia, confirmation is generally required [2].
When T1D is suspected, clinicians may measure islet autoantibodies and, in selected cases, C-peptide to help classify diabetes. Neither a negative single antibody test nor detectable C-peptide automatically excludes early or slowly progressive autoimmune diabetes.
Stages of type 1 diabetes and screening
Autoimmune T1D may progress through presymptomatic stages: stage 1 usually involves multiple diabetes-associated autoantibodies and normal glycemia; stage 2 involves dysglycemia without classic symptoms; and stage 3 is clinically apparent diabetes [2].
People with a first-degree relative affected by T1D may discuss autoantibody screening and monitoring, especially where specialized pathways are available. Some people with stage 2 disease may qualify for teplizumab, an anti-CD3 monoclonal antibody authorized in certain jurisdictions to delay progression to stage 3 T1D in eligible adults and children aged 8 or older. It is not a cure for established T1D, and requires expert screening and counseling.
Insulin treatment: basal and meal-related needs
Most individuals need both basal insulin, covering glucose production between meals and overnight, and prandial (bolus) insulin, covering food intake and corrections. This may be delivered through multiple daily injections (MDI) or an insulin pump. Insulin dosing depends on age, body size, carbohydrate intake, activity, illness, insulin sensitivity and the individual’s treatment plan [1].
| Insulin approach | What it does | Important safety point |
|---|---|---|
| Rapid-acting insulin analogues | Mealtime and correction dosing. | Timing depends on product and meal; excess doses can rapidly cause hypoglycemia. |
| Long-acting basal analogues | Background insulin between meals and overnight. | Do not omit basal insulin during most illnesses or when not eating, unless specifically directed by the care team. |
| Insulin pump (CSII) | Continuous rapid-acting insulin delivery with adjustable boluses. | Infusion interruption can cause rapid ketosis/DKA; backup injection plan is essential. |
| AID/hybrid closed-loop | Combines pump, CGM and algorithm to adjust insulin delivery. | Still needs user education, meal information, device troubleshooting and backups. |
Standard regimens are individualized; insulin-to-carbohydrate ratios, correction factors and insulin sensitivity should be taught by a diabetes team rather than copied from generic internet examples.
2026 ADA update: CGM and automated insulin delivery
The 2026 ADA pharmacologic treatment section states that integrating CGM soon after diagnosis improves glycemic outcomes and reduces hypoglycemia, and CGM is now standard care for most people with T1D. AID systems are preferred where they can be used safely, with evidence of better time in range and fewer low-glucose episodes compared with less automated approaches [1,3].
AID does not remove the need for education. Patients and caregivers should learn to recognize sensor errors, change infusion sites, respond to persistent highs or lows, count carbohydrates where applicable and use backup insulin injections during pump failure. Cost and access may limit availability, and effective MDI with monitoring remains a valid plan when technology is unavailable.
Understanding A1C and time in range
A1C estimates average glucose exposure over roughly three months, although accuracy can be affected by anemia, hemoglobin variants, pregnancy and altered red-cell survival. For many nonpregnant adults, the ADA suggests an individualized A1C goal around below 7%, but a less or more stringent target may be appropriate [4].
For many adults using CGM, a typical goal is more than 70% of time between 70 and 180 mg/dL (3.9–10.0 mmol/L), while keeping time below 70 mg/dL low, generally under 4% and time below 54 mg/dL under 1%. Goals require adjustment for pregnancy, children, frailty, hypoglycemia unawareness or substantial comorbidity [3,4].
A good A1C does not rule out dangerous frequent hypoglycemia. Review CGM patterns, overnight values, severe episodes, variability and quality of life instead of using a single number in isolation.
Recognizing and treating hypoglycemia
Hypoglycemia can cause shaking, sweating, hunger, palpitations, headache, irritability, confusion or seizure. Level 1 is below 70 mg/dL (3.9 mmol/L); level 2 is below 54 mg/dL (3.0 mmol/L), and severe hypoglycemia is defined by the need for help from another person, regardless of the exact meter reading [4].
For an awake person who can safely swallow, a common approach is 15 g of fast-acting carbohydrate, rechecking in 15 minutes and repeating if still low. Some individuals need a different amount based on age, treatment and automated delivery. Examples include measured glucose tablets or juice. Do not give food or drink to an unconscious or seizing person.
For severe hypoglycemia, caregivers should use prescribed glucagon according to device instructions and call emergency services. Diabetes teams should provide training and discuss nasal or injectable glucagon where available [4].
Diabetic ketoacidosis: a medical emergency
DKA occurs when insulin is insufficient and the body produces excess ketones, causing metabolic acidosis and dehydration. Symptoms can include vomiting, abdominal pain, rapid deep breathing, fruity breath, extreme thirst, confusion and drowsiness. Patients with suspected DKA require urgent hospital assessment for fluid, electrolyte and insulin management [2,4].
DKA can occasionally develop when glucose is not extremely high, especially with certain drugs or reduced carbohydrate intake. Do not rely solely on glucose levels to rule out dangerous ketosis. Blood beta-hydroxybutyrate measurement is useful for evaluating suspected ketone accumulation when available.
Sick-day rules: never ignore ketones
Illness can increase insulin requirements even when appetite is low. A personalized sick-day plan should explain how to check glucose more frequently, when to test blood or urine ketones, how to maintain fluids and carbohydrate intake, and when to contact a clinician [2,4].
Do not stop all insulin simply because a person cannot eat: background insulin is usually still necessary to prevent ketosis. However, meal boluses and corrections may need individualized changes. If a pump fails, switch promptly to the team-provided backup injection plan. Persistent vomiting, rising ketones, difficulty drinking or worsening breathing requires urgent evaluation.
Food and carbohydrate counting
People with T1D can generally eat a varied balanced diet rather than avoiding all carbohydrates. They often benefit from learning carbohydrate counting and matching prandial insulin to meals, while also accounting for fat/protein effects, timing and activity. Consistent meal patterns can reduce variability, but the approach should match the individual’s insulin strategy [1,2].
Extremely restrictive diets can increase nutrient, hypoglycemia and ketosis concerns and should not be started without a knowledgeable clinician or dietitian. Alcohol may increase delayed hypoglycemia risk, particularly overnight.
Exercise and type 1 diabetes
Regular physical activity improves fitness, cardiovascular health, mood and quality of life. However, exercise can either lower or raise glucose depending on intensity, insulin on board and stress hormones. Plan glucose checks before, during and after activity as appropriate and carry rapid carbohydrate and glucagon when indicated.
Exercise should be postponed and ketones assessed when glucose is very high with evidence of insulin deficiency or illness. A diabetes professional can help develop safe strategies for aerobic and resistance exercise and overnight monitoring after prolonged activity.
Long-term screening and complications
Care includes regular assessment for retinopathy, kidney disease, neuropathy, foot problems and cardiovascular risk. Timing depends on age at diagnosis, duration, pregnancy and individual factors. Periodic urine albumin-to-creatinine ratio, kidney function, retinal assessment and foot evaluation are important in eligible patients [2].
T1D is associated with other autoimmune conditions, notably thyroid disease and celiac disease. Screening should follow guideline and clinical indications. Address blood pressure, lipid levels, smoking, vaccinations and emotional burden as part of care.
Psychosocial care and diabetes distress
Constant calculations, alarms, cost and fear of hypoglycemia can create substantial diabetes distress or burnout. A supportive team should assess wellbeing without blaming patients for imperfect readings. Mental-health support, education, family or school accommodations, and access to supplies can be central to sustained safety [2,3].
Children and adolescents need age-appropriate responsibility sharing. Parents and caregivers should know how to manage severe hypoglycemia, pump failure, sick days and school activities; complete dependence on a mobile application is unsafe without emergency backups.
Pregnancy with type 1 diabetes
Pregnancy requires preconception counseling, tighter individualized glucose targets and specialist antenatal diabetes care. The 2026 ADA pregnancy standards recommend CGM in pregnant people with T1D and generally aim for fasting glucose below 95 mg/dL and specified postmeal targets, balanced against severe hypoglycemia risk [5].
Insulin requirements may change substantially across pregnancy. People planning pregnancy should review medicines, folate, retinopathy and kidney function with the treating team. Generic nonpregnant CGM or insulin targets should not simply be copied into pregnancy.
Frequently asked questions
Can adults develop type 1 diabetes?
Yes. Autoimmune T1D can first become clinically apparent at any age.
Can type 1 diabetes be treated without insulin?
In established insulin-deficient T1D, no; insulin is essential to prevent DKA.
Does CGM replace insulin injections?
No. CGM measures glucose; insulin must still be delivered through injections or a pump.
Does an automated pump prevent all low or high glucose?
No. AID improves outcomes but still needs meal management, sensor and infusion troubleshooting, and backups [1].
Should basal insulin be stopped during vomiting illness?
Usually no, because insulin deficiency can cause DKA. Follow an individualized sick-day plan and seek urgent assessment if unable to keep fluids down.
Can positive autoantibodies predict future T1D?
Multiple confirmed autoantibodies with staging information can indicate presymptomatic autoimmune diabetes, requiring specialist interpretation and follow-up.
Key takeaways
Type 1 diabetes management centers on reliable insulin replacement and prevention of low glucose and DKA. The 2026 ADA Standards consider CGM standard care for most patients and prefer automated insulin delivery when safely usable. Personalize glucose goals, maintain a sick-day and pump-failure plan, and treat severe hypoglycemia or suspected DKA as an emergency.
References
- American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1). doi:10.2337/dc26-s009.
- American Diabetes Association. Standards of Care in Diabetes—2026: complete supplement. Diabetes Care. 2026;49(Suppl 1).
- American Diabetes Association. Diabetes technology: Standards of Care in Diabetes—2026. Diabetes Care. 2026.
- American Diabetes Association. Glycemic goals, hypoglycemia, and hyperglycemic crises: Standards of Care in Diabetes—2026. Diabetes Care. 2026.
- American Diabetes Association. Management of diabetes in pregnancy: Standards of Care in Diabetes—2026. Diabetes Care. 2026.
- Centers for Disease Control and Prevention. About type 1 diabetes. CDC; accessed 9 Nov 2026.
Medical disclaimer: Educational information only. Insulin doses, CGM/AID configuration and carbohydrate ratios require personal clinician instructions. Severe low blood sugar, seizure, altered consciousness, vomiting with ketones or symptoms of diabetic ketoacidosis require emergency care.
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.